ONCY's pelareorep can differentiate Big Pharma's ICI ONCY's pelareorep has the ability to differentiate a Big Pharma company's immune checkpoint inhibitor (ICI) from the competition by targeting sub-populations of cancer patients through the use of predictive and diagnostic biomarkers, and the synergistic enhancement the immune checkpoint inhibitors in combination with pelareorep, thus enabling Big Pharma the ability to address sub-populations of patients with unmet cancer treatment needs.
As previously posted "This level of unmet need combined with the potential of PD-1/PD-L1 therapies to expand into earlier settings, including neo-adjuvant, as well as opportunities to enter new indications, is fueling frantic development activity" according to the recent IQVIA report on PD-(L)1 inhibitors
The benefits of combining ONCY's pelareorep with immune checkpoint inhibitors (ICIs) and other I/O agents are that combinations with pelareorep are able to overcome drug therapy resistance and instead result in a deep and durable response, including the stimulation of a strong T-cell response and the direct modification of tumor immunogenicity through the remodeling of the tumor microenvironment (TME).
ONCY's ability to remodel the TME and the stimulate the innate and adaptive immune systems provides for a modified tumor ecosystem that enables the addition of an immune checkpoint inhibitor, which results in a synergistically effective I/O combination therapy that can treat various cancers and sub-populations of cancers with unmet treatment needs in earlier treatment scenarios (i.e. neo-adjuvant)